AlphaStocks

AZN vs VCEL

ASTRAZENECA PLC vs Vericel Corp — Side-by-Side Stock Comparison

AZN

ASTRAZENECA PLC

8.4

Strong Buy

$200.99

VCEL

Vericel Corp

4.3

Weak

$32.58

AZN vs VCEL: Which is the Better Investment?

ASTRAZENECA PLC (AZN) scores 8.4/10 while Vericel Corp (VCEL) scores 4.3/10 on AlphaStocks' composite model. ASTRAZENECA PLC has the higher composite rating of Strong Buy. On a P/E basis, ASTRAZENECA PLC trades at 30.4x, making it the more attractively priced of the two.

This comparison is algorithmically generated and is not financial advice.

MetricAZNVCEL
Scores & Fundamentals
Composite Score8.4/104.3/10
RatingStrong BuyWeak
Price$200.99$32.58
P/E Ratio30.4102.9
ROE21.9%2.3%
Market Cap$312B$2B
Fair Value$192.63
Dividend Yield1.6%
Sector Rank#3 of 1127#783 of 1127
Model Verdicts
PiotroskiStrongStrong
BuffettStrongNeutral
GrahamCautionCaution
LynchNeutralLimited Data
GreenblattNeutralLimited Data
View full AZNanalysis →View full VCELanalysis →
Compare any two stocks →

AZN vs VCEL: Which Stock Scores Higher?

ASTRAZENECA PLC (AZN) and Vericel Corp (VCEL) are among the most compared stocks in the Health Care sector. AZN currently leads with a composite score of 8.4/10 (Strong Buy) compared to VCEL's 4.3/10 (Weak).

The AlphaStocks composite score evaluates each stock across four dimensions: Quality (business strength measured by Piotroski F-Score and Buffett quality criteria), Value (discount to intrinsic worth using Graham, Lynch, and Greenblatt models), Momentum (6-month price trend), and Timing (a confirmation signal that requires both value and momentum to align). A higher composite score indicates stronger overall fundamentals combined with favorable market conditions.

This comparison uses the same scoring framework for both companies, ensuring an apples-to-apples evaluation. Scores are recalculated daily after market close using data from SEC filings and market prices. Read the full methodology to understand how each model contributes to the composite score.

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer